Spotlight on ceftazidime/avibactam: a new option for MDR Gram-negative infections.
about
Therapeutic options for carbapenem-resistant Enterobacteriaceae infections.Can Ceftazidime-Avibactam and Aztreonam Overcome β-Lactam Resistance Conferred by Metallo-β-Lactamases in Enterobacteriaceae?Carbapenem-Resistant Enterobacteriaceae.Successful ceftazidime-avibactam treatment of MDR-KPC-positive Klebsiella pneumoniae infection in a patient with traumatic brain injury: A case report.Every cloud has a silver lining.Antimicrobial Activities of Ceftazidime-Avibactam and Comparator Agents against Clinical Bacteria Isolated from Patients with Cancer.Inhibition of the β-Lactamase BlaMab by Avibactam Improves the In Vitro and In Vivo Efficacy of Imipenem against Mycobacterium abscessus.Inhibition by Avibactam and Clavulanate of the β-Lactamases KPC-2 and CTX-M-15 Harboring the Substitution N132G in the Conserved SDN Motif.Recent advances in the understanding and management of Klebsiella pneumoniae.Contribution of horizontal gene transfer to the emergence of VIM-4 carbapenemase producer Enterobacteriaceae in Kuwait.Comparison of Two Phenotypic Algorithms To Detect Carbapenemase-Producing Enterobacteriaceae.Structural Insights into the TLA-3 Extended-Spectrum β-Lactamase and Its Inhibition by Avibactam and OP0595.Bacterial zincophore [S,S]-ethylenediamine-N,N'-disuccinic acid is an effective inhibitor of MBLs.Antimicrobial Activities of Aztreonam-Avibactam and Comparator Agents against Contemporary (2016) Clinical Enterobacteriaceae Isolates.Antimicrobial Activity of Ceftazidime-Avibactam Tested against Multidrug-Resistant Enterobacteriaceae and Pseudomonas aeruginosa Isolates from U.S. Medical Centers, 2013 to 2016.Comparison of two commercial carbapenemase gene confirmatory assays in multiresistant Enterobacteriaceae and Acinetobacter baumannii-complex.and Characterization of NOSO-502, a Novel Inhibitor of Bacterial Translation
P2860
Q38918458-3899316C-6DAE-464C-9FE5-B252B87730C8Q38975480-2504B6E5-9A7A-4323-8D41-BF964787BCA4Q39273184-E5B5904B-E53E-4C36-B9AA-03E134D2F2C6Q40109997-5B352B57-BD6D-4FAB-BC8B-B160CE3DCE46Q40206174-9C312A4C-9F2A-4F43-B258-A57FA722981DQ40361152-39E2C1A5-7EA7-483B-93E6-E2F4741B5776Q40368667-B87DFB84-7066-4FDE-96C0-866F4B06780AQ42319612-EDE59557-46E0-4413-8E51-5BA6A5F9249BQ42367237-35B514B8-ADCA-4022-A3A5-3262262615EDQ47272978-BEB91AE9-0272-4D6E-98CE-6E39E6CA6594Q47805309-EE104B23-CD51-4F6B-B3F3-F06499A79990Q48713306-4EEB43F5-E5DF-441A-A62E-998B00AE72F9Q49549528-3CB6AEAA-EC6A-4476-BA19-35AED0F24898Q50072886-2494C968-4549-4D9F-A018-AEA0ED1489F5Q53728436-19A212F1-404E-40BA-923F-F78A48854AF2Q54204342-D80DD2FC-6FD0-42D0-829E-EFE7B9B092B1Q58700580-58249171-DAF8-4A94-A59E-2FFEEFC54674
P2860
Spotlight on ceftazidime/avibactam: a new option for MDR Gram-negative infections.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
Spotlight on ceftazidime/avibactam: a new option for MDR Gram-negative infections.
@en
type
label
Spotlight on ceftazidime/avibactam: a new option for MDR Gram-negative infections.
@en
prefLabel
Spotlight on ceftazidime/avibactam: a new option for MDR Gram-negative infections.
@en
P2860
P356
P1476
Spotlight on ceftazidime/avibactam: a new option for MDR Gram-negative infections.
@en
P2093
Marco Falcone
P2860
P304
P356
10.1093/JAC/DKW239
P407
P577
2016-07-17T00:00:00Z